.Nature Medicine, Published online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) therapy of patients with HER2+ state-of-the-art breast cancer cells as well as energetic or even steady brain metastases presented constant intracranial task and also systemic efficacy of T-DXd.